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httpcense.Abstract Objectives: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is
a major public health problem. Recognition of comorbid heart dysfunction in such patients is often
difﬁcult. The aim of this work is to evaluate the role of N-terminal pro B-type natriuretic peptide
(Nt-pro BNP) in AECOPD with respiratory failure.
Patients and methods: This studywas conductedon20patientswithAECOPDand respiratory fail-
ure. All patients were subjected to history taking, clinical examination, routine laboratory investiga-
tions, arterial blood gases analysis, echocardiography and estimation of plasma level of NT-pro BNP.
Results: Patients were classiﬁed into 3 groups: Group I: those without heart dysfunction (40%),
Group II: those with diastolic heart failure (40%), and Group III: those with systolic heart failure
(20%). NT-pro BNP mean ± SD in group I was 673.38 ± 416.02, in group II 1962 ± 847.88, and
in group III 6776.75 ± 1433.59 pg/ml. Therewas a statistically signiﬁcant difference between the three
groups (p= 0.001). NT-pro BNP showed a statistically signiﬁcant inverse correlation with pH
(p= 0.005), ejection fraction (p= 0.007) and a direct one with both left ventricular systolicFaculty of Medicine, Egypt.
om (T.S. Morsi).
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58 H. El Mallawany et al.(p= 0.008) and diastolic (p= 0.016) dimensions andE/A (p= 0.016). TheNT-pro BNP signiﬁcantly
decreased after recovery fromAECOPD (p= 0.030). The receiver operating characteristic curve dem-
onstrated a ruling out of LVdysfunction inAECOPDof a sensitivity of 100%and a speciﬁcity of 60%;
and a ruling in of a sensitivity of 48% and a speciﬁcity of 67%.
Conclusion: Plasma BNP is usually elevated in AECOPD and is related to right or left ventricular
systolic or diastolic dysfunction.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
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Chronic obstructive pulmonary disease (COPD) remains a ma-
jor public health problem. It has some signiﬁcant extrapulmo-
nary effects that may contribute to the severity in individual
patients. Its pulmonary component is characterized by airﬂow
limitation that is not fully reversible. The airﬂow limitation is
usually progressive and associated with an abnormal inﬂam-
matory response of the lung to noxious particles or gases.
The chronic airﬂow limitation characteristic of COPD is
caused by a mixture of small airway disease (obstructive bron-
chiolitis) and parenchymal destruction (emphysema), the rela-
tive contributions of which vary from person to person [1].
An exacerbation of COPD is deﬁned as ‘‘an event in the
natural course of the disease characterized by a change in
the patient’s baseline dyspnea, cough, and/or sputum that is
beyond normal day-to-day variations, is acute in onset, and
may warrant a change in regular medication in a patient with
underlying COPD’’ [2]. The most common causes of an exac-
erbation are the infection of the tracheobronchial tree and air
pollution, but the cause of approximately one-third of severe
exacerbations cannot be identiﬁed [3]. In COPD there is a
background of mild inﬂammation. There is a general belief
that exacerbations are episodes where the inﬂammatory pro-
cess is enhanced. There are varying degrees of inﬂammation
affecting the large and small airways as well as the alveoli,
resulting in mucus hypersecretion, airway narrowing and alve-
olar destruction. The main mediators directly responsible for
this damage are proteinases released by inﬂammatory cells,
particularly neutrophils, that are found in abundance in the
bronchial secretions of patients with COPD [4].
Pulmonary arterial hypertension (PAH) develops late in the
course of the natural history of patients with COPD and is
associated with the development of severe hypoxemia. It is a
major cardiovascular complication of COPD and is associated
with the development of right ventricular hypertrophy
(namely, ‘‘cor pulmonale’’) and has a poor prognosis [5]. In
patients with COPD, without severe hypoxemia or hypercap-
nia, the pulmonary artery pressure (PAP) is usually normal
or only slightly elevated when measured at rest, but may rise
abnormally during exercise. Despite slow progression, the
presence of pulmonary hypertension implies a poor prognosis
in patients with COPD [6].
Echocardiography is a useful tool to diagnose pulmonary
hypertension and cor pulmonale. However, measurement can-
not be achieved in all patients since hyperinﬂation of the chest
will alter sound-wave transmission through the chest. Invasive
measurements of pulmonary arterial pressure by right heart
catheterization remain the ‘‘gold standard’’ measurement of
the pulmonary arterial pressure [7].It has become clear that cardiac events are the major cause
of death for patients with COPD in all stages of disease. These
associations could be from shared risk factors, most notably
cigarette smoking. Increases in C-reactive protein, for exam-
ple, represent a major risk factor for cardiovascular disease.
In this context, COPD is also an inﬂammatory disease and
increases in C-reactive protein are present in patients with
COPD [8]. However, there are mechanical and physiologic
relationships that could account for these associations.
Clinically, it is often difﬁcult to distinguish between cardiac
and pulmonary disease as a cause for dyspnea. The assessment
of brain natriuretic peptide (BNP) may prove useful in this
regard.
It has been almost 50 years since the ﬁrst anatomical clues
to an endocrine function of the heart were reported. Electron
microscopy revealed secretory granules in atrial myocytes,
which structurally resembled storage granules in peptide-
hormone-producing cells [9]. It was only in 1981, however, that
Adolfo de Bold and his coworkers put the endocrine heart to
the test and infused extracts of atrial tissue into anesthetized
rats. The infusion elicited prompt renal excretion of sodium
and water, decreased the blood pressure, and increased the
hematocrit. The substance was logically named atrial natri-
uretic factor [10]. Soon after, this factor was puriﬁed and iden-
tiﬁed as a peptide of 28 amino acid residues and was named
atrial natriuretic peptide (ANP) [11]. This discovery of a new
peptide paved the way for the later identiﬁcation of the differ-
ent but structurally related peptide in porcine brain: brain
natriuretic peptide (BNP) [12]. However, BNP was found to
be produced mainly in the heart, and the name ‘‘brain natri-
uretic peptide’’ now is often replaced with ‘‘B-type natriuretic
peptide’’ [13].
N-terminal fragments from the cardiac precursor peptides
proANP and proBNP were also found to circulate in plasma
and provided new molecular markers for biochemical detec-
tion of heart failure. Atrial and ventricular myocytes differ
in their endocrine apparatus. It is a well established fact that
atrial myocytes contain secretory granules for proBNP, in con-
trast, ventricular myocytes in the healthy heart do not seem to
produce these granules, and do not contain proBNP derived
peptides [14].
The aim of this work is to evaluate the role of N-terminal
pro B-type natiuretic peptide (NT-pro BNP) in acute exacerba-
tion of chronic obstructive pulmonary disease with respiratory
failure.
Patients and methods
This study was conducted in the intensive care unit of the chest
disease department in main Alexandria University Hospital. It
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tion of chronic obstructive pulmonary disease with respiratory
failure.
All patients were subjected to full history taking, thorough
clinical examination emphasizing on signs of COPD, respira-
tory failure, cor pulmonale and heart failure. Electrocardio-
gram was carried out to all patients. Venous blood sample
was taken and analyzed for complete blood picture, renal
and liver function tests, fasting blood glucose level, prothrom-
bin activity, total serum protein, albumin, lactate dehydroge-
nase content and C-reactive protein. Arterial blood sample
was drawn from the radial artery and analyzed for hydrogen
ion concentration (pH), partial pressure of arterial oxygen
(PaO2), partial pressure of arterial carbon dioxide (PaCO2),
oxygen saturation and bicarbonate (HCO3) level.
Echocardiography was performed (HP screen, 100 CF
Hewlett Packard) for the assessment of pulmonary artery
hemodynamics by doppler analysis of pulmonary ﬂow measur-
ing the acceleration time (AT) (time from onset to the peak of
the ejection ﬂow velocity), left ventricular end systolic dimen-
sion (LVES), left ventricular end diastolic dimension (LVED),
right ventricular dimension (RVD), left ventricular ejection
fraction (LVEF), peak velocities of blood ﬂow during early
diastolic ﬁlling (E wave) and atrial contraction ﬁlling (A wave)
then the ratio (E/A) is calculated.
Peripheral blood sample was taken and examined for
N-terminal pro B-type natiuretic peptide (NT-pro BNP) level.
N-terminal brain natriuretic peptidewasmeasuredwith aRoche
Diagnostics proBNP assay on an Elecsys 2010 analyser. In this
two-site assay 20 ll of sample is incubated with biotinylated
polyclonal antibody plus a different polyclonal antibody labeled
with a ruthenium complex. Both antibodies are directed to the
proBNP (amino acids 1-76 of proBNP) region. Following incu-
bation the bound fraction is separated with streptavidin-coated
microparticles and quantitated by chemiluminescence. Data
provided by Roche Diagnostics show that total assay precision
ranges from 1.8% at 800 pmol/l to 2.7% at 20.7 pmol/l and the
detection limit is 0.6 pmol/l. Crossreactivity with other peptides
including amino-terminal proANP peptides, C-type natriuretic
peptide, and components of the renin-angiotensin systemwas all
<0.001%.
Results
We classiﬁed the patients according to history, clinical exami-
nation and echocardiographic ﬁnding into 3 groups: Group I:Table 1 Patients’ characteristics of the three groups.
Age years Gender Smoking histo
M F
Group I 59.38 ± 9.05 7 (87.5%) 1 (12.5%) 6 (75.0%)
Group II 58.13 ± 7.74 5 (62.5%) 3 (37.5%) 5 (62.5%)
Group III 54.25 ± 15.2 4 (100%) 0 (0.0%) 4 (100%)
t-Value 0.358
p 0.704
x2 2.813 2
p 0.245 0.368
M: male; F: female; DOS: duration of smoking; PH: previous hospitalizat
exacerbation of COPD.COPD exacerbation with no heart failure (8 patients: 40%),
GroupII: COPD exacerbation with diastolic heart failure (8
patients: 40%), and Group III: COPD exacerbation with
systolic heart failure (4 patients: 20%).
The patients’ characteristics of all 20 patients showed a
mean ± SD age of 57.85 ± 9.37 years ranging from 47 to
76 years. Sixteen (80%) patients were males and four (20%)
were females. Fifteen (75%) patients were smokers and ﬁve
(25%) were non smokers. The mean ± SD duration of smok-
ing was 32 ± 8.71 years ranging from 15 to 43 years. The
duration of COPD had a mean ± SD of 9.9 ± 5.34 years
ranging from 4 to 20 years. Twelve (60%) patients were hyper-
tensive and four (20%) were diabetic. Fifteen (75%) patients
were previously hospitalized for acute exacerbation of COPD
(AECOPD).
The patients’ characteristics of the three groups are shown
in Table 1. In group I the mean ± SD age was
59.38 ± 9.05 years ranging from 51 to 76 years, in group II
it was 58.13 ± 7.74 years ranging from 47 to 68 years, in group
III it was 54.25 ± 15.2 years ranging from 42 to 76 years; there
was no statistical signiﬁcant difference between the 3 groups.
In group I there were seven male patients (87.5%) and 1 female
(12.5%); in group II there were ﬁve male patients (62.5%) and
3 females (37.5%); and in group III all patients (100%) were
males. In group I six patients were smokers (75%) and 2 were
non smokers (25%); in group II ﬁve patients were smokers
(62.5%) and 3 were non smokers (37.5%); and in group III
all patients were smokers (100%). In group I the mean ± SD
duration of smoking was 30 ± 10.49 years ranging from 15 to
40 years, in group II it was 35.6 ± 5.86 years ranging from 30
to 43 years, and in group III it was 30 ± 10 years ranging from
20 to 40 years; there was no statistical signiﬁcant difference be-
tween the 3 groups. The mean ± SD duration of COPD in
group I was 10 ± 4.63 years ranging from 5 to 15 years, in
group II it was 9.13 ± 5.51 years ranging from 4 to 20 years,
in group III it was 11.25 ± 7.5 years ranging from 5 to
20 years; there was no statistical difference between the three
groups. Hypertension was present in 4 (50%) patients in group
I, in 5 (62.5%) patients in group II and in 3 (75%) patients in
group III. Diabetes mellitus was present in 1 (12.5%) patient in
group I and in 3 (37.5%) patients in group II. History of pre-
vious cardiac disease, notably ischemic heart disease was given
by 3 (37.5%) patients in group II and by all 4 (100%) patients
in group III. Regarding previous hospitalization for AE-
COPD, it was recorded in 5 (62.50%) patients in group I, in
6 (75.00%) patients in group II and in all 4 (100%) patientsry DOS years Duration of COPD years PH for AECOPD
30 ± 10.49 10 ± 4.63 5 (62.50%)
35.6 ± 5.86 9.13 ± 5.51 6 (75.00%)
30 ± 10 11.25 ± 7.5 4 (100%)
0.625 0.195
0.553 0.825
2
0.368
ion; COPD: chronic obstructive pulmonary disease; AECOPD: acute
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tween the three groups.
The clinical examination of all the twenty patients showed a
mean ± SD heart rate of 107.4 ± 12.6 beats per minute rang-
ing from 90 to 140 beats per minute; a mean ± SD systolic
blood pressure of 139 ± 17.4 mmHg ranging from 120 to
190 mmHg; a mean ± SD diastolic blood pressure of
89 ± 8.52 mmHg ranging from 80 to 110 mmHg. The
mean ± SD respiratory rate was 25.95 ± 4.21 breaths per
minute ranging from 20 to 40 breaths per minute. The
mean ± SD temperature was 37.47 ± 0.82 C ranging from
37 to 40 C. Wheezes and diminished air entry were found in
all patients. Bilateral basal crackles were heard in 9 (45%) pa-
tients; congested neck veins were seen in 9 (45%) patients; he-
patic enlargement was found in 4 (20%) patients and bilateral
lower limb edema was found in 12 (60%) patients.
On comparing the three groups, the mean ± SD heart rate
in group I was 108.75 ± 11.88 beats per minute, in group II
100.88 ± 6.58 beats per minute, and in group III
117.75 ± 18.08 beats per minute. There were no signiﬁcant dif-
ferences between the three groups (p= 0.08). The mean ± SD
systolic blood pressure in group I was 145 ± 21.38 mmHg, in
group II 137.5 ± 15.81 mmHg, and in group III
130 ± 8.16 mmHg. There were no signiﬁcant differences be-
tween the three groups (p= 0.375). The mean ± SD diastolic
blood pressure in group I was 93.75 ± 10.61 mmHg, in group
II 87.5 ± 4.63 mmHg, and in group III 82.5 ± 5 mmHg.
There were no signiﬁcant differences between the three groups
(p= 0.072). The mean ± SD respiratory rate in group I was
25.63 ± 3.74 breaths per minute, in group II 24.63 ± 0.92
breaths per minute, and in group III 29.25 ± 7.63 breaths
per minute. There were no signiﬁcant differences between the
three groups (p= 0.198).
The arterial gasometric studies of all 20 patients showed a
mean ± SD pH of 7.29 ± 0.09 ranging from 7.05 to 7.42; a
mean ± SD PaCO2 of 68 ± 21.63 mmHg ranging from 34.9
to 103.8 mmHg; a mean ± SD PaO2 of 87.65 ± 89.45 mmHg
ranging from 38.4 to 213 mmHg; a mean ± SD oxygen satura-
tion of 86.74 ± 9.47% ranging from 65.8% to 99.3%; a
mean ± SD bicarbonate level of 33.095 ± 8.08 mEq/l ranging
from 23 to 51.2 mEq/l and a mean ± SD PaO2/FIO2 of
109.73 ± 51.3 ranging from 96 to 236. Most patients were al-
ready put on oxygen and some of them intubated when the
arterial blood gases sample was taken.
The comparison of the arterial gasometric study of the
three groups is shown in Table 2. The mean ± SD pH in group
I was 7.25 ± 0.1, in group II 7.27 ± 0.09, and in group III
6.59 ± 1.45. There were no signiﬁcant differences between
the three groups (p= 0.175). The mean ± SD PaCO2 in groupTable 2 Arterial gasometric study in the three groups.
pH PaCO2 (mmHg) PaO2 (mmH
Group I 7.25 ± 0.1 67.21 ± 20.46 91.78 ± 73.2
Group II 7.27 ± 0.09 79.59 ± 17.98 63.51 ± 16.4
Group III 6.59 ± 1.45 46.4 ± 15.89 97.68 ± 27.1
t-Value 1.934 4.207 1.569
p 0.175 0.033* 0.237
pH: hydrogen ion concentration; PaCO2: arterial partial pressure of carb
saturation in arterial blood; HCO3: bicarbonate level; FIO2: fraction of i
* Statistical signiﬁcance at p< 0.05.I was 67.21 ± 20.46 mmHg, in group II 79.59 ± 17.98 mmHg,
and in group III 46.4 ± 15.89 mmHg. There was a signiﬁcant
statistical difference between group II and group III
(p= 0.033). The mean ± SD PaO2 in group I was
91.78 ± 73.22 mmHg, in group II 63.51 ± 16.42 mmHg, and
in group III 97.68 ± 27.18 mmHg. There were no signiﬁcant
differences between the three groups (p= 0.237). The
mean ± SD oxygen saturation in group I was
85.59 ± 11.89%, in group II 85.56 ± 7.35%, and in group
III 91.43 ± 8.75%. There were no signiﬁcant differences be-
tween the three groups (p= 0.569). The mean ± SD bicar-
bonate level in group I was 30.6 ± 7.85 mEq/l, in group II
35.93 ± 8.47 mEq/l, and in group III 32.2 ± 7.92 mEq/l.
There were no signiﬁcant differences between the three groups
(p= 0.435). The mean ± SD PaO2/FIO2 in group I was
110.44 ± 40.74, in group II 97.38 ± 41.56, and in group III
134 ± 75.61. There were no signiﬁcant differences between
the three groups (p= 0.505).
Regarding the laboratory investigations of all 20 patients,
the hemoglobin level ranged from 11.5 to 16.5 g/dl with a
mean ± SD of 13.93 ± 1.8 g/dl; the hematocrit level ranged
from 34.2% to 57.5% with a mean ± SD of 45.86 ± 6.84%;
the white blood cells ranged from 3.95 to 30.2 cell/mm3 with
a mean ± SD of 10.68 ± 6.36 cell/mm3; the creatinine level
ranged from 0.5 to 2.2 mg/dL with a mean ± SD of
1.11 ± 0.505 mg/dL; the C-reactive protein (CRP) level ran-
ged from 9.2 to 202 mg/l with a mean ± SD of
35.38 ± 42.51 mg/l; the erythrocyte sedimentation rate (ESR)
in the ﬁrst hour ranged from 4 to 80 mm/hr with a mean ± SD
of 34.63 ± 24.36 mm/hr; the ESR in the second hour ranged
from 15 to 110 mm/hr with a mean ± SD of
61.73 ± 32.09 mm/hr and the NT-pro BNP ranged from 54
to 8852 pg/ml with a mean ± SD of 2409.50 ± 2453.95 pg/ml.
The comparison of the laboratory results of the three
groups is shown in Table 3. The hemoglobin level mean ± SD
in group I was 14.51 ± 1.69 g/dl, in group II 13.91 ± 2.04 g/
dl, and in group III 12.43 ± 0.4 g/dl. There were no signiﬁcant
differences between the three groups (p= 0.247). The hemato-
crit level mean ± SD in group I was 47.23 ± 7.57%, in group
II 46.59 ± 6.78%, and in group III 40.33 ± 2.08%. There
were no signiﬁcant differences between the three groups
(p= 0.324). The white blood cells mean ± SD in group I
was 9.03 ± 4.88 cell/mm3, in group II 10.26 ± 4.62 cell/mm3,
and in group III 16.27 ± 12.19 cell/mm3. There were no signif-
icant differences between the three groups (p= 0.248). The
erythrocyte sedimentation rate (ESR) in the ﬁrst hour in group
I was 18.75 ± 15.71 mm/hr, in group II 43.86 ± 24.31 mm/hr,
and in group III 50.25 ± 24.66 mm/hr. There was a statistical
signiﬁcant difference between group I and groups II and IIIg) O2 sat (%) HCO3 (mEq/l) PaO2/FIO2
2 85.59 ± 11.89 30.6 ± 7.85 110.44 ± 40.74
2 85.56 ± 7.35 35.93 ± 8.47 97.38 ± 41.56
8 91.43 ± 8.75 32.2 ± 7.92 134 ± 75.61
0.583 0.878 0.712
0.569 0.435 0.505
on dioxide; PaO2: arterial partial pressure of oxygen; O2 sat: oxygen
nspired oxygen.
Table 3 Laboratory investigations in the three groups.
HB HCT WBC ESR1 CRP NT-pro BNP
Group I 14.51 ± 1.69 47.23 ± 7.57 9.03 ± 4.88 18.75 ± 15.71 23.68 ± 12.79 673.38 ± 416.02
Group II 13.91 ± 2.04 46.59 ± 6.78 10.26 ± 4.62 43.86 ± 24.31 49.53 ± 63.65 1962 ± 847.88
Group III 12.43 ± 0.4 40.33 ± 2.08 16.27 ± 12.19 50.25 ± 24.66 28.9 ± 10.31 6776.75 ± 1433.59
t-Value 1.529 1.211 1.524 4.046 0.76 69.871
p 0.247 0.324 0.248 0.038* 0.484 0.001*
HB: hemoglobin; HCT: hematocrite; WBC: white blood cell; ESR1: erythrocyte sedimentation rate in 1st hour; CRP: C reactive protein; NT-
pro BNP: N-terminal pro B-type natiuretic peptide.
* Statistical signiﬁcance at p< 0.05.
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38.63 ± 25.46 mm/hr, in group II 74.86 ± 27.73 mm/hr, and
in group III 85 ± 24.14 mm/hr. There was a statistical signiﬁ-
cant difference between group I and groups II and III
(p= 0.014). The CRP level in group I was 23.68 ±
12.79 mg/l, in group II 49.53 ± 63.65 mg/l, and in group III
28.9 ± 10.31 mg/l. There were no signiﬁcant differences be-
tween the three groups (p= 0.484). The NT-pro BNP
mean ± SD in group I was 673.38 ± 416.02 pg/ml ranging
from 54 to 1541 pg/ml, in group II 1962 ± 847.88 pg/ml rang-
ing from 1050 to 3588 pg/ml, and in group III
6776.75 ± 1433.59 pg/ml ranging from 5620 to 8852 pg/ml
(Fig. 1). There was a statistically signiﬁcant difference between
the three groups regarding NT-pro BNP (p= 0.001).
The echocardiographic parameters of all 20 patients
showed a mean ± SD LVES of 3.5375 ± 1.09 cm ranging
from 2.03 to 6.25 cm; a mean ± SD LVED of
4.955 ± 0.99 cm ranging from 3.65 to 7.92 cm; a mean ± SD
LVEF of 60.22 ± 11.65% ranging from 38% to 80%; a
mean ± SD RVD of 3.33 ± 0.86 cm ranging from 2.1 to
5.32 cm; a mean ± SD pulmonary ﬂow acceleration time of
75.9 ± 15.344 ms ranging from 55 to 120 ms and a
mean ± SD E/A ratio of 1.44 ± 0.2 ranging from 0.8 to 2.1.
The comparison of the echocardiographic ﬁndings of the
three groups is shown in Table 4. The mean ± SD LVES in
group I was 3.02 ± 0.61 cm, in group II 3.25 ± 0.67 cm, andFigure 1 Box plot illustrating N-terminal pro B-type natiuretic
peptide (NT-pro BNP) in the 3 studied groups. There was a
statistically signiﬁcant difference between the three groups
(p= 0.001).in group III 5.14 ± 1.13 cm. There was a statistical signiﬁcant
difference between group III and the other two groups
(p= 0.001). The mean ± SD LVED in group I was
4.51 ± 0.58 cm, in group II 4.74 ± 0.63 cm, and in group III
6.28 ± 1.25 cm. There was a statistical signiﬁcant difference
between group III and the other two groups (p= 0.004).
The mean ± SD LVEF in group I was 68.63 ± 8.7%, in
group II 59.75 ± 6.43%, and in group III 44.38 ± 7.97%.
There was a statistical signiﬁcant difference between group
III and the other two groups (p= 0.001). The mean ± SD
RVD in group I was 3.20 ± 1.06 cm, in group II
3.51 ± 0.89 cm, and in group III 3.22 ± 0.17 cm. There was
no signiﬁcant differences between the three groups
(p= 0.762). The mean ± SD E/A in group I was 1.2 ± 0.4,
in group II 1.98 ± 0.3, and in group III 0.87 ± 0.2. There
was a statistical signiﬁcant difference between group II and
the other two groups (p= 0.002).
The correlations of plasma NT-pro BNP with other param-
eters are shown in Table 5. Plasma NT-pro BNP did not show
any signiﬁcant correlation with the age (p= 0.967), duration
of smoking (p= 0.891), duration of COPD (p= 0.235), heart
rate (p= 0.314), respiratory rate (p= 0.219), systolic blood
pressure (p= 0.133), PaO2 (p= 0.412), PaCO2 (p= 0.105),
HCO3 (p= 0.843), PaO2/FIO2 (p= 0.32), hematocrit
(p= 0.062), WBC (p= 0.082), ESR in the ﬁrst hour
(p= 0.059), ESR in the second hour (p= 0.053), CRP
(p= 0.714), RVD (p= 0.837) and AT (p= 0.743). Plasma
NT-pro BNP showed a statistically signiﬁcant inverse correla-
tion with the diastolic blood pressure (p= 0.02), hemoglobin
(p= 0.034), pH (p= 0.005) and LVEF (p= 0.007) (Fig. 2).
However, the plasma NT-pro BNP showed a statistically sig-
niﬁcant direct correlation with LVES (p= 0.008), LVED
(p= 0.016) and E/A (p= 0.016).
The NT-pro BNP was repeated in 14 patients after recovery
from the exacerbation, its mean ± SD value signiﬁcantly de-
creased from 1298.4 ± 848.57 pg/ml to 539.48 ± 484.56 pg/
ml (p= 0.030).
The receiver operating characteristic (ROC) curve demon-
strated a cut off value of 900 pg/ml for ruling out the presence
of LV dysfunction in AECOPD with a sensitivity of 100% and
a speciﬁcity of 60%. The cut off value for ruling in the presence
of LV dysfunction in AECOPD was 2180 pg/ml with a sensi-
tivity of 48% and a speciﬁcity of 67%.
Discussion
Chronic obstructive pulmonary disease is a common disease
with a steadily increasing prevalence and mortality. COPD is
Table 4 Echocardiographic parameters in the three groups.
LVES (cm) LVED (cm) LVEF (%) RVD (cm) E/A
Group I 3.02 ± 0.61 4.51 ± 0.58 68.63 ± 8.7 3.20 ± 1.06 1.2 ± 0.4
Group II 3.25 ± 0.67 4.74 ± 0.63 59.75 ± 6.43 3.51 ± 0.89 1.98 ± 0.3
Group III 5.14 ± 1.13 6.28 ± 1.25 44.38 ± 7.97 3.22 ± 0.17 0.87 ± 0.2
t-Value 11.534 7.754 13.222 0.277 8.931
p 0.001* 0.004* 0.001* 0.762 0.002*
LVES: left ventricular end systolic dimension; LVED: left ventricular end diastolic dimension; LVEF: left ventricular ejection fraction; RVD:
right ventricular dimension; E/A: ratio of peak velocities of blood ﬂow between early diastolic ﬁlling (E) and atrial contraction ﬁlling (A).
* Statistical signiﬁcance at p< 0.05.
Table 5 Correlations of plasma NT-ProBNP.
Ph PaO2 PaCO2 PaO2/FIO2 CRP AT RVD LVEF E/A
BNP r 0.602 0.194 0.373 0.234 0.09 0.078 0.049 0.584 0.531
p 0.005* 0.412 0.105 0.32 0.71 0.74 0.837 0.007* 0.016*
BNP: N-terminal pro B-type natiuretic peptide; pH: hydrogen ion concentration; PaO2: arterial partial pressure of oxygen; PaCO2: arterial
partial pressure of carbon dioxide; FIO2: fraction of inspired oxygen; CRP: C reactive protein; AT: pulmonary ﬂow acceleration time; RVD:
right ventricular dimension; LVEF: left ventricular ejection fraction; E/A: ratio of peak velocities of blood ﬂow between early diastolic ﬁlling (E)
and atrial contraction ﬁlling (A).
* Statistical signiﬁcance at p< 0.05.
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Figure 2 The signiﬁcant inverse correlation between the N-
terminal pro B-type natiuretic peptide (NT-pro BNP) and the left
ventricular ejection fraction (EF).
62 H. El Mallawany et al.the only major cause of death whose incidence is on the in-
crease [15] and is expected to be the third leading cause of
death worldwide by 2020, exceeded only by heart disease and
stroke [15,16].
The most severe cardiac sequel of chronic lung disease is the
load on the right ventricle due to pulmonary hypertension with
the development of cor pulmonale; characterized by hypertro-
phy and/or dilatation of the right ventricle because of a pri-
mary impairment of lung function and/or lung structure.
Levels of natriuretic peptides can be useful in diagnosing car-
diac complications in patients with chronic of lung disease, asthey tend to be higher in patients with heart and pulmonary
disease rather than in pulmonary disease alone [17]. The
ANP and BNP are released primarily from heart but circulate
as hormones to act in various tissues in the body. They induce
vasodilatation, natriuresis and diuresis. Although ANP is pref-
erentially synthesized and secreted from the atria and BNP
from the ventricles both can be synthesized in either chamber
under pathologic conditions. Both BNP and NT-proBNP pep-
tides are derived from the 134-amino acid precursor pre pro
BNP. They have been shown to be closely correlated to each
other and exhibit parallel changes across a broad spectrum
of age, renal function, and LVEF. However, they are not inter-
changeable because the level of NT-pro BNP tends to be about
10-fold higher than that of BNP [18].
The plasma BNP levels in patients with stable COPD who
did not have any symptoms or physical ﬁndings of pulmonary
hypertension or cor pulmonale were previously reported to be
signiﬁcantly higher than those of healthy subjects and patients
with severe asthma, and the level increased signiﬁcantly with
disease severity [19]. Another study notiﬁed that in patients
with chronic hypercapnic respiratory failure NT-proBNP lev-
els were markedly elevated compared to healthy controls and
after excluding patients with concomitant heart or renal
impairment, levels were still increased. Again the NT-proBNP
level correlated with the degree of respiratory impairment [20].
Moreover, plasma BNP level during exacerbations was also re-
ported to be signiﬁcantly higher than during stable disease [19–
21]. We found a signiﬁcant decrease in the level of NT-pro
BNP after recovery from AECOPD. Such observation has
been reported formerly [21]. This higher level of BNP was
explained by decrease in expiratory ﬂow, leading to air-trap-
ping and hyperinﬂation of the lung which can impair the
cardiac functions [22]. Another hypothesis is that the
hypoxia-mediated contraction of the small pulmonary
Role of N-terminal pro B-type natriuretic peptide in acute exacerbation of chronic obstructive pulmonary disease 63arterioles results in increased pulmonary arterial pressure and
consequently right ventricular dysfunction [21]. In the present
study, the NT-pro BNP level was elevated in all patients, those
with and those without left heart impairment. However, the le-
vel was signiﬁcantly higher in those with left ventricular sys-
tolic or diastolic dysfunction. Also, nineteen of our twenty
patients had their pulmonary artery pressure elevated so right
cardiac stress could not be excluded.
The absence of signiﬁcant correlation between BNP level
and both PaO2 and PaCO2 was previously reported in stable
COPD patients [19] and those with exacerbation [21]. The for-
mer authors explained their ﬁndings by the fact that the sever-
ity of COPD according to the guidelines is deﬁned by the FEV1
value alone [19]. The latter authors speculated that BNP levels
summarize and integrate the extent of left ventricular systolic
dysfunction, left ventricular diastolic dysfunction, valvular
dysfunction, and right ventricular dysfunction. Hence, right
ventricular dysfunction secondary to hypoxic vasoconstriction
reﬂects only one of four potential BNP triggers. The presence
and the extent of the other three factors vary extensively from
patient to patient and is to a large extent independent of right
ventricular dysfunction [21]. We found no signiﬁcant correla-
tion between NT-pro BNP level and both PaO2 and PaCO2.
However, most of our patients were already put on oxygen
supplementation upon enrollment in the study and it was not
possible clinically to stop the oxygen supply; but still, there
was no signiﬁcant correlation between NT-pro BNP level
and PaO2/FIO2.
Previous reports described a signiﬁcant correlation between
BNP level and both PaO2 [20,23,24] and PaCO2 [20]. The in-
verse correlation with PaO2 was not only reported in the ab-
sence of oxygen supplementation but in its presence as well
[20]. It was shown also that patients with severe hypoxemia
had a higher level of BNP [20,23,25]. Hypoxia causes natri-
uretic peptides secretion by two mechanisms: the ﬁrst hypoxia
is the most important factor in the development of pulmonary
hypertension and right ventricular wall stretch or tension by
induction of pulmonary vasoconstriction, the second hypoxia
cause direct release of BNP from myocardium [20,23]. The
low oxygen tension as such, without increase in the heart mass,
causes an increase in natriuretic peptide synthesis [26]. More-
over, it was observed that plasma BNP levels were signiﬁcantly
decreased by long term oxygen therapy [23].
We found signiﬁcant inverse correlation between pH and
N-terminal proBNP level. A previous study found that a small
drop in pH slows down the contractile response to stretch but
signiﬁcantly increases the ANP secretion during stretch. These
changes are probably due to impaired calcium handling during
acidosis, which leads to an increase in diastolic calcium when
the muscle is stretched [27]. Also, it was previously reported
that various systolic Doppler indices and pulmonary arteries’
dimensions were signiﬁcantly correlated with the arterial pH,
indicating that the more the pH becomes acidotic the more
the pulmonary hemodynamics become deranged. The correla-
tion was well established in spite of the very narrow range of
pH present in this study [28].
In our study we did not ﬁnd a signiﬁcant correlation be-
tween pulmonary artery ﬂow acceleration time and level of
N terminal proBNP. The absence of elevated BNP levels in
the presence of pulmonary artery hypertension (PAH) was pre-
viously reported [25]. It was speculated that plasma BNP levels
did not reﬂect pulmonary hypertension unless there was leftventricular failure or valvular heart diseases [25]. Some authors
reported that BNP levels in patients with steady-state PAH did
not differ from the values detected in patients without PAH
[21]. Others found BNP to be a predictor of PAP levels in
chronic pulmonary embolism and interstitial lung disease
groups but not in COPD and chronic respiratory failure.
Again, a previous study established no relation between mean
PAP and plasma peptide concentrations in patients with termi-
nal parenchymal lung disease and normal left ventricular func-
tion; the relation was only recognized when including patients
with primary pulmonary hypertension [29].
In contrast, signiﬁcant correlation between plasma BNP le-
vel and PAP was reported [19,20,24,30], and higher BNP levels
were reported in the presence of PAH [30]. It was even stated
that BNP level determination has a role in the diagnosis of cor
pulmonal in COPD patients [24]. Increased BNP values have
been found to be correlated with pulmonary hypertension in
chronic lung disease of different etiologies and to serve as a
risk factor for mortality [31]. Moreover, exercise-induced
BNP levels elevation may be a useful alternative to pulmonary
artery catheterization in identifying COPD patients without
right ventricular dysfunction at rest who are likely to beneﬁt
from long-term oxygen therapy [32]. The inability of our study
to demonstrate a direct correlation between N terminal pro
BNP level and acceleration time may be related to small sam-
ple population and the presence of other factors affecting NT-
pro BNP level in plasma.
We found statistically signiﬁcant difference in NT-pro BNP
level between AECOPD with and without left ventricular dys-
function. The BNP measurements are helpful in the diagnosis
of left heart dysfunction in COPD patients either in stable con-
dition or during acute exacerbation of COPD [20,33]. It is also
able to uncover new onset of left heart failure associated with
weaning difﬁculties from mechanical ventilation in COPD pa-
tients [33]. Different BNP assays are helpful diagnostic indica-
tors for selecting patients who should undergo
echocardiographic screening to detect previously unknown
heart failure, in a population of stable elderly patients with a
primary care diagnosis of COPD [34].
We found also a direct signiﬁcant correlation between NT-
pro BNP level and both LVES and LVED and a signiﬁcant in-
verse correlation between NT-pro BNP level and LVEF. Such
direct [35] and inverse [19,35] correlations were previously re-
ported in COPD patients.
Heart failure is a clinical syndrome that can result from any
structural or functional cardiac disorder that impairs ventricu-
lar ﬁlling or ejection [36]. The signs and symptoms of heart
failure are nonspeciﬁc (dyspnea, exercise intolerance, fatigue,
weakness) and often can be attributed to other conditions,
such as pulmonary disease, anemia, hypothyroidism, depres-
sion, and obesity [37]. When the syndrome is associated with
a reduced ejection fraction, it is often called ‘‘systolic heart
failure.’’ When the ejection fraction is normal or near normal
(preserved), terms such as ‘‘diastolic heart failure,’’ ‘‘heart fail-
ure with preserved systolic function,’’ ‘‘heart failure with
normal ejection fraction,’’ and ‘‘heart failure with a preserved
ejection fraction’’ have all been advocated [36]. Cardiac
catheterization remains the gold standard for demonstrating
impaired relaxation and ﬁlling, because it provides direct
measurement of ventricular diastolic pressure. However, the
balance of beneﬁt, harm, and cost argues against its routine
use in diagnosing diastolic dysfunction [37]. Doppler
64 H. El Mallawany et al.echocardiography has assumed the primary role in the nonin-
vasive assessment of cardiac diastolic function and is used to
conﬁrm the diagnosis of diastolic heart failure [37,38].
BNP blood levels were reported to be signiﬁcantly and
markedly higher in patients with diastolic heart failure than
those without in COPD patients [39]. We found a signiﬁcant
direct correlation between plasma NT-pro BNP and E/A. On
echocardiography, the peak velocity of blood ﬂow across the
mitral valve during early diastolic ﬁlling corresponds to the
E wave. Similarly, atrial contraction corresponds to the A
wave. Under normal conditions, E is greater than A and the
E/A ratio is approximately 1.5. In early diastolic dysfunction,
relaxation is impaired and, with vigorous atrial contraction,
the E/A ratio decreases to less than 1.0. As the disease pro-
gresses, left ventricular compliance is reduced, which increases
left atrial pressure and, in turn, increases early left ventricular
ﬁlling despite impaired relaxation. This paradoxical normaliza-
tion of the E/A ratio is called pseudonormalization. In patients
with severe diastolic dysfunction, left ventricular ﬁlling occurs
primarily in early diastole, creating an E/A ratio greater than
2.0 [38].
It was speculated that the most appropriate use of BNP as-
says in routine practice would be as an exclusion test of left
ventricular dysfunction, where positive values would result in
further cardiac investigation, including echocardiography
[40]. In the present study the ROC curve for plasma NT-pro
BNP showed a cut off value for ruling out LV dysfunction
in AECOPD more speciﬁc and more sensitive than the cut
off value for ruling in. Our cut off values for ruling out and
ruling in LV dysfunction in AECOPD were not that different
from those reported by previous studies [41]. However, those
latters demonstrated better sensitivity and speciﬁcity, being
higher for values of ruling out [41]. In COPD patients, those
cut off values were found to be greater than those usually rec-
ommended for suspecting LV dysfunction [41]. This could be
explained by a supraphysiologic secretion of natriuretic pep-
tides in AECOPD patients because of the presence of hypox-
emia, pulmonary hypertension, and RV dysfunction [41–43].
Plasma BNP is usually elevated in AECOPD. After recov-
ery, its level signiﬁcantly decreases. The elevation of plasma
NT-pro BNP level is related to overt left ventricular systolic
or diastolic dysfunction or right ventricular stress from ele-
vated pulmonary artery pressure. Even in the absence of
apparent cardiac dysfunction, elevated NT-pro BNP levels in
AECOPD could not be dissociated from heart stress which
increases from the pulmonary physiological changes in such
condition. However, plasma NT-pro BNP can help in follow
up patients with AECOPD.Conﬂict of interest
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